Partner to your idea

10/11

2/3 12/13 4/5 14/15 16/17 6/7 18 8/9 19 10/11 20/21

Contents page

12/13 14/15 16/17 18 19 20/21

2/3

AT A GLANCE

4/5

CREATING VALUE THROUGH PARTNERSHIPS

6/7

VACCINES

8/9

RESEARCH & DEVELOPMENT

10/11

ONCOLOGY DIABETES

12/13

Ophthalmology Aging

14/15

Fibrosis and wound repair Infectious Diseases

16/17

Immuno-inflammation Biologics

18/19

Exploratory Unit Asia Pacific Early to Candidate Lead Generation to Candidate Realization

20/21

Pharmaceutical Customer Solutions Prospective and Strategic Initiatives

22/23

Worldwide connected network of selected partners Recent deal flow overview

24

Industrial Affairs Sales & Marketing

2/3 4/5 6/7 8/9 10/11 12/13 14/15 16/17 18 19 20/21

CHRISTOPHER A. VIEHBACHER Chief Executive Officer Sanofi-aventis

What empassions me most about our industry is that it never slows down or stops evolving. After centuries of research, the explosion of science is palpable all around us and the opportunity for innovation is simply astounding. Sanofi-aventis has always been regarded as one of the world’s leading R&D based companies and more recently, we have also been recognized as a partner of choice. With 33 external deals signed in 2009 alone, 20 of which were in R&D, the success of our partnership strategy is clear, but why? The reasons are manifold but, put simply, it is because we understand. We understand the need to foster an environment where scientists and developers have the freedom to think and create. As result of our history and experience, we understand the science and the real public health needs of tomorrow. We understand the markets and have the resources and expertise to ensure products can move through the pipeline to the market as fast as possible, whilst ensuring adherence to the highest safety and quality standards. And through our diverse culture and geographical spread, the network of sanofi-aventis can ensure access to both traditional and emerging markets, local knowledge and the production and commercialization of the approved products. But, most importantly, we understand that our partners have their own objectives, a culture specific to their team and a need for a partner to work collaboratively to create success for both. The research paradigm is changing and whilst we will continue to foster innovation within the company, we realize that in order to respond to patients’ needs in the future, we need to work together and create partnerships wherever the best science and technology may be. By pooling the creativity and expertise of world-renowned researchers and professionals internally and externally, together with our partners we can ensure the best innovations, which will ultimately lead to discoveries benefiting the existing and future patients that are waiting for us.

1

At a glance

Sanofi-aventis’ ambition is to become a diversified global healthcare leader, focused on patients’ needs. Group strategy is based on three key principles in order to deliver long-term sustainable growth: • Increasing innovation in Research & Development • Seizing external growth opportunities • Adapting group structures for future challenges Sanofi-aventis has core strengths in the field of healthcare with five growth platforms: emerging markets, vaccines, consumer healthcare, diabetes treatment, innovative products and cancer treatment.

29,306 €29,306 m 2009 net sales – Gross of 6.3% compared with 2008 on a reported basis

22 105,000 4,5834th 110 Approximately

105,000

22

employees WORLDWIDE

RESEARCH & DEVELOPMENT SITES

€4,583 m

PRESENT IN

4th

investment in r&d in 2009 Representing 15.6% of net sales

largest pharmaceutical group in the world as of end 2009

110 countries

A WORLD LEADER

N°2

N°1

N°3

N°5

IN HUMAN VACCINES

IN EUROPE

IN EMERGING MARKETS

IN ANIMAL HEALTH AS OF END 2009

IN CONSUMER HEALTHCARE WITH THE ACQUISITION OF CHATTEM, OUR NEW US CONSUMER HEALTCARE PLATFORM

5 Growth platforms* €7,356 m +19.0%

EMERGING MARKETS

€3,774 m +19.4%

DIABETES BRANDS

€3,483 m +19.2%

VACCINES CONSUMER HEALTHCARE

€1,430 m +26.8%

NEW PRODUCTS * 2009 net sales, growth is at constant exchange rates.

2/3

Creating value through partnerships

Openness to discovery “This is a collaborative relationship without restrictive preconditions between two leading organizations. Our scientists will continue to freely explore cutting-edge research and publish their work, with the added benefit of advancing the science through this unique association that provides access to extensive resources at sanofi-aventis. Further collaboration and scientific exchange will be reinforced through annual Salk/sanofi-aventis research retreats and extended working lab visits between scientists from both organizations.” William BRODY, CEO SALK

The Salk Institute for Biological Studies in La Jolla, California, is an independent non-profit organization dedicated to fundamental discoveries in the life sciences, the improvement of human health and the training of future generations of researchers. The sanofi-aventis Regenerative Medicine Program at the Salk Institute is a close research collaboration to support the Institute’s stem cell facility and provide flexible financial support to individual scientists to accelerate innovative research projects in public health.

18 33 2 33

Partnerships and acquisitions in 2009

18

2

R&D partnerships/ in-licensing deals SIGNed IN 2009 R&D ACQUISITIONS IN 2009

“

Professional teams dedicated to your ideas

“Prior to founding Alopexx I was involved with in-licensing activities at several large pharmaceutical companies. I know firsthand the efforts it takes for a team to properly evaluate and license an opportunity. The professionalism, diligence and responsiveness displayed by sanofi’s in-licensing team were of the highest caliber. We are investigating novel approaches to the treatment and prevention of staphylococcal and other bacterial infections. We were gratified to see the sanofi team’s grasp of the potential and clinical utility of our antibody. We continue to be impressed with the input and guidance provided by sanofi as we move forward with clinical development. It gives us the greatest confidence that ongoing and future plans with our antibody will meet with similar interactions and success.” Daniel VLOCK, CEO Alopexx

Novel collaboration structures

“We are delighted to have established this global partnership with sanofi-aventis, a world leader in healthcare. This partnership, effective today with a leading actor at the forefront of life sciences, should enable us to better showcase French research abroad. We are very pleased to stand side-byside with sanofi-aventis to conduct research from fundamental science to patient application.” Pr. André SYROTA, Chairman of AVIESAN

Sanofi-aventis signed in February 2010 a research partnership with AVIESAN (the French Life Sciences and Healthcare Alliance), comprised of the CEA, CNRS, INRA, INRIA, Inserm, Institut Pasteur, IRD, Conference of University Presidents and Conference of regional and university hospital CEOs. This is the first time such a partnership has been signed with all the players of the academic research community in the field of healthcare in France.

“We are very pleased to have entered into this partnership with the National Alliance for Life Sciences and Healthcare, which is a major breakthrough in terms of public-private partnerships in France. By pooling the creativity and expertise of a multitude of world-renowned researchers, we are sure that this fruitful collaboration will boost innovation in life sciences in France, and ultimately lead to major discoveries that will benefit patients. Through this agreement, sanofi-aventis confirms once again its commitment to developing research and innovation in France.” Christopher A. VIEHBACHER CEO of sanofi-aventis

4/5

Vaccines

Sanofi pasteur, the vaccines division of sanofi-aventis group is seeking partners who will share the company’s pursuit of innovation and drive for excellence. Our diverse culture and geography allow us to collaborate effectively with a broad array of partners around the world. We are not only at the forefront of conquering newly targeted diseases, but also leading the way in expanding immunization across all age groups, including adolescents and the elderly. This leadership has translated into outstanding success in the industry, and our company has experienced a recent period of unprecedented growth.

12,500 491 3,483 €491 m in r&d investments in 2009

12,500 employees

€3,483 m 2009 NET SALES IN VACCINES

Sanofi pasteur is interested in potential partnering opportunities in the field of active and passive human immunization.

Domains of interest Vaccines, monoclonal antibodies and supporting technologies for prevention and treatment of infectious diseases: • Novel antigens for vaccine development • Monoclonal antibodies, including antigens as targets for monoclonal antibody development • Antigen discovery and characterization • Carrier proteins and protein-polysaccharide conjugation methods or alternative technologies

Existing alliances/ partnership: • • • • •

BD (Becton, Dickinson and Company) Chumakov Institute CSL KaloBios Syntiron

Agents to enhance vaccine immune responses – such as adjuvants and immunomodulators: • Adjuvants, particularly those that drive Th1 and Th2 immune responses • Vaccine vectors intended to enhance or modify immune responses • Characterization, modulation and assay of protective immune responses • Areas of basic immunology applicable to vaccine development, such as studies of innate immunity, immune escape mechanisms, and immunoregulation New vaccine delivery systems: • New ways to administer vaccines • Vaccine vectors suitable for nasal or oral use

Partnering Contacts

Tools for improving vaccine and monoclonal antibody research, development and production: • Animal models of human diseases • Development and application of new technologies in the areas of genomics and proteomics • Bioinformatics techniques for data handling and analysis • Prokaryotic or eukaryotic cell lines for antigen production • Fermentor and bioreactor technology • Downstream processing and purification processes • Preservatives and stabilizers • Identification of biological markers for evaluating the efficacy of prophylactic or therapeutic interventions for infectious diseases • Epidemiological studies relevant to the use of vaccines and immunotherapeutics

Jeffrey Almond, PhD Vice President, Discovery and External Research & Development Campus Mérieux 1541 avenue Marcel Mérieux 69280 Marcy L’Étoile – France Tel: +33 4 3737 9453 [email protected] Allan Jarvis, Jr. PhD Vice President, Corporate Development Sanofi pasteur Inc. Discovery Drive Swiftwater PA 18370, USA Tel: +1 570 957 5525 [email protected]

For more information please visit www.sanofipasteur.com 6/7

Research & Development

From preferred partners to preferred networks: A commitment to health. The objective of sanofi-aventis R&D is to find new solutions to address the individual patient’s needs by understanding disease processes and actively integrating that understanding into healthcare management. At this time of unprecedented opportunities, and considering the complexity of today’s science, creative solutions and continued research collaboration are required. The new sanofi-aventis R&D values networks and focuses on partnership and collaboration. Aiming to incorporate innovation into the main fabric of R&D, we set up a unique structure revolving around networks of creativity spread across regions, technologies and scientific areas of excellence. Supporting these networks are disciplined and efficient core processes, creating a performance-driven environment that fosters fast decision-making and the empowerment of our teams. Our strategic vision for R&D focuses on seven major areas with critical unmet medical needs: Diabetes, Oncology, Ophthalmology, Aging, Infectious Diseases, Fibrosis & Wound Repair and Immuno-Inflammation, while taking into account regional specificities with the establishment of an Asia-Pacific R&D Center.

“Looking into the future, the renewed R&D is moving a step further from preferred partners to preferred networks. Such networks will not just serve sanofi-aventis and individual institutions or laboratories, rather it will enable all partners within the network to access the resources and expertise of everyone else so as to form a vibrant research ecosystem and create more value than we ever could alone – for improving health throughout the world.” Marc Cluzel Executive Vice President Research & Development

22 11,0 15.6 60 31 22

RESEARCH & DEVELOPMENT SITES

11,000

APPROXIMATE NUMBER OF R&D EMPLOYEES WORLDWIDE EXCLUDING VACCINES

€4,583 m 2009 RESEARCH AND DEVELOPMENT SPEND REPRESENTING

15.6% OF NET SALES

60%

of the compounds in our pharma portfolio is developed through partnerships as of APRIL 2010

31%

of our pharma portfolio is composed of biological compounds as of APRIL 2010

8/9

Oncology Sanofi-aventis’ Oncology Division – a new and unique organization merging patient needs and innovative science – was recently created as part of current transforming efforts and demonstrates sanofi-aventis’ commitment to oncology as a major strategic pillar. The Oncology Division is a fully integrated business unit comprising the full R&D chain from discovery to development and commercialization. Its goal is to provide solutions that have a major impact on patients with cancer – a Patient Focused Innovation Strategy – and, in the process, to build a sustainable oncology business. The division is headquartered in Cambridge, MA, USA, one of the world’s most important centers for biotech research and Vitry-sur-Seine, France, where a significant part of sanofi-aventis’ oncology research and development activities have been historically located. These dual locations in the US and Europe will provide us with excellent opportunities to forge strategic external partnerships, leverage the local talent, and embrace many of the successful elements from the biotech employee culture – including accountability, creativity, and entrepreneurialism. It is supported by sanofi-aventis’ corporate R&D network with clinical research units in several countries and a biotechnology platform for monoclonal antibodies in Vitry-sur-Seine, France.

Existing alliances/ partnership: • • • • • •

Dyax Exelixis ImmunoGen Merrimack Micromet Regeneron

Domains of interest Scientific areas: • Growth and development pathways related to cancer dependence • Synthetic lethality • Cancer metabolism related to cancer dependence • Targeted therapies and technologies enabling targeted therapies • Companion diagnostics • Innovative therapies that provide substantial improvements for patients • Best in class and/or first in class; small molecules or biologics • Compounds suitable for combination therapy aimed at additive/synergistic effects, in particular with sanofi-aventis commercialized or pipeline products • Supportive care products if demonstrated benefit over existing therapies Development Stage: • Discovery or pre-clinical stage through all clinical development stages to already commercialized oncology products

Partnering Contacts External Opportunity contact: Alain Curaudeau VP and Head of Strategy & Portfolio Management Global Oncology Division Sanofi-aventis, US, Inc 200 Crossing Blvd, BX2-812A Bridgewater, New Jersey 08807, USA Tel: +1 908 231 4000 [email protected] Business Development contact Tanja S. Weber VP Oncology 174 avenue de France 75635 Paris cedex 13 – France Tel: +33 1 53 77 40 00 [email protected]

Diabetes Sanofi-aventis’ Diabetes Division is a newly created and fully integrated structure comprising all functions working on diabetes from discovery to commercialization in our 12 major markets. The Diabetes Division portfolio generated €3.8 bn sales in 2009 including a broad spectrum of therapeutic solutions, the Division offers a full range of devices to simplify usage of insulin for patients, soon to be complemented by easy-to-use and reliable blood glucose monitors. The division ambition is to become a “360°” partner of the patient: delivering bestin-class and integrated solutions to diabetic patients. The division is committed to place the patient in the heart of the organization through the integration of new pharmacological targets and innovative approaches and the seamless connection of diagnostics, treatment and monitoring. To leverage the inspiring heritage from Hoechst that has made sanofi-aventis a strong partner for diabetic patients and healthcare professionals for over 85 years, Frankfurt will serve as the primary site for product and device innovation. Acknowledging diabetes as a truly global epidemic, 2 secondary locations are established in France and the US ensuring the appropriate connectivity with global stakeholders and patients worldwide.

Domains of interest Scientific areas: New approaches to improve the daily life of patients with diabetes, in particular: • Innovative approaches for the diagnosis, prevention and treatment of Type 1 and/or Type 2 diabetes • First in class and best in class therapeutics (small molecules, insulins and other biologics) and vaccines • Microvascular and defined macrovascular (central and peripheral) complications of diabetes, wound healing • Regenerative medicine incl. stem cells for use in diabetes • Innovative device approaches, monitoring systems and integrated solutions • Biomarkers, diagnostics, and bioinformatics • Systems biology (biologic insights into mechanisms for target selection) • Personalized therapies in diabetes • Formulation technologies aimed at improving existing or future products • Compounds and approaches for combination therapy in particular with sanofi-aventis products • Prevention of diabetes (Hypercholesterolemia, Obesity etc.) • Anti-inflammatory therapies with impact on diabetes Development Stage: • Discovery or pre-clinical stage through all clinical development stages to already commercialized diabetes products

Existing alliances/ partnership: • • • •

AgaMatrix CureDM Wellstat Therapeutics Zealand Pharma

"We are excited to partner with sanofi-aventis because they share our core beliefs – people with diabetes need more accurate blood glucose meters and our technology delivers high accuracy. With their global presence and sterling reputation, we believe this partnership will enable patients worldwide to easily access high accuracy blood glucose testing." Sonny Vu and Sridhar Iyengar Co-Founders of AgaMatrix

Partnering Contacts External Opportunity contact Ulrich Stilz Global Head of Innovation & External Networking – Diabetes Division Industriepark Hoechst, Bldg G838 D- 65926 Frankfurt am Main Tel: +49 69 305 80710 [email protected] Business Development contact Christian Lerche Associate VP Diabetes & Metabolism 174 avenue de France 75635 Paris cedex 13 – France Tel: +33 1 53 77 40 00 [email protected]

10/11

Ophthalmology Ophthalmology is a high potential market, which is expected to grow significantly over the years to come. This growth is likely to be driven by innovation and new products, premium pricing with no significant reimbursement issues and societal trends, such as aging populations and the diabetes epidemics. Created in 2005, Fovea Pharmaceuticals is a biopharmaceutical company, specialized in development and commercialization of drugs for the treatment of ocular diseases and based at the Institut de la Vision in Paris (France). Fovea has a portfolio of three clinical compounds, a unique technology platform and several discovery programs dedicated to back of the eye diseases. Acquisition of Fovea Pharmaceuticals and the gene therapy collaboration with Oxford Biomedica, both accomplished in 2009 were the first steps towards the recent creation of the Ophthalmology Division of sanofi-aventis. This new division will combine the expertise and resources needed from both Fovea and sanofi‑aventis to significantly grow the business and demonstrate the efficacy of products through regulatory clinical development. With this goal in mind, the Ophthalmology Division is interested in further examining potential partnering opportunities in the field of ocular diseases.

Existing alliances/ partnership: • • • • • • • • • •

Dyax Genzyme John Hopkins University Montreal University ORA Oxford Biomedica Paris Vision Institute Pennsylvania University Regeneron University of Geneva

Domains of interest Agents and devices to treat retinal diseases: • Dry atrophic Age-related Macular Degeneration (AMD) • Retinal vascular diseases: wet AMD, Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME) • Vitroretina surgery compounds and devices Agents to treat ocular surface diseases: • Persistent allergic conjunctivitis • Dry Eye • Uveitis • Infection and inflammation Agents to treat Glaucoma: • Intra-ocular-pressure (IOP) lowering • Neuroprotection Drug Delivery Systems and Devices: • Sustained delivery to the retina • Glaucoma non topical sustained delivery Imaging tools and Biomarkers: • New Optical Coherance Tomography (OCT) and coupling with Adaptative Optics

Partnering Contacts FOVEA Pharmaceuticals Institut de la Vision 17 rue Moreau, 75012 Paris – France Tel: +33 1 44 16 42 43 www.fovea-pharma.com Pierre Belichard Chief Operating Officer [email protected]

Marie-Laure Bouttier Business Development Associate [email protected]

Aging There is an unprecedented, pervasive and enduring global demographic change. The world’s population is aging and it has profound implications for many facets of human life. The Aging Unit focuses on providing integrated healthcare solutions for the elderly. We aim to treat age-related diseases, globally, to provide practical solutions for the elderly as well as to sustain their functional well-being.

Domains of interest Quality of life: • Chronic Pain • Vitality and fatigue • Circadian rhythm perturbations • Hormonal changes • Urogenital disorders, benign prostate hyperplasia, incontinence

Existing alliances/ partnership: • • • • • • • •

California Institute of Technology DiaTral (Medicen) IMI-EuroPain MIT Regeneron Rockefeller University Salk Institute TRANSAL (Medicen)

Sensory disorders: • Hearing disorders • Aged-related ophthalmologic conditions • Exploration of other sensory disorders (olfactory, taste) Disabilities from cardiac, vascular and cerebral origin: • Stroke: prevention and acute treatment-management of patients after the event • Alzheimer’s disease and related co-morbidities • Parkinson’s disease Musculoskeletal diseases: • Osteoarthritis • Osteoporosis • Sarcopenia Other domains of interest: • Nutraceuticals and Cosmeceuticals • Skin: healing, aging and bedsores • Biology of aging – biomarkers of aging – cell dysfunction (mitochondrial DNA), transcription factors and genes, telomeres and longevity, cell homeostasis, metabolism and diet • Stem cell therapy • Delivery systems, new formulations, polypills, drug devices and technologies designed to improve compliance, sensing technologies, adherence and observance of drug treatment, and overall quality of life in the elderly, personalized medicine • E-health

Partnering Contacts External Opportunity contact: Kenneth I. Maynard Head, Business Development Office Sanofi-aventis, US, Inc. 200 Crossing Blvd, BX2-812A, Bridgewater, New Jersey 08807 USA Tel: +1 908 231 4000 [email protected] Business Development contact: Marion ROY Associate VP Aging, Cardiology & Internal Medicine 174 avenue de France 75635 Paris cedex 13 – France Tel: +33 1 53 77 40 00 [email protected]

12/13

Fibrosis and Wound Repair The injury and repair of tissues and organs has far reaching consequences for patients and thus represents an area of growth potential for pharmaceuticals. From renal failure and cirrhosis to the rejection of transplanted organs, fibrotic diseases are often devastating and usually debilitating, with few non-surgical options for patients. The research and development of innovative healthcare solutions for the treatment of fibrosis, scarring or wound repair is an exciting new area for sanofi-aventis. Any novel therapeutic must address unmet medical needs of patients and have potential for superior benefits compared to current therapies, leading to a high probability for approval and reimbursement. Healthcare solutions could include small molecules, bio-conjugated small molecules, peptides, proteins, microRNA, RNAi, monoclonal antibodies, cell therapies and botanical therapeutics, which may potentially be combined with innovative therapeutic delivery systems. The Unit’s scope extends from drug concept through clinical proof of concept.

Domains of interest • Therapeutic solutions for tissue injury, fibrosis and wound repair including small molecules, biologics, botanical drugs, tissue engineering... • Technologies that improve diagnostics related to tissue fibrosis, re-modelling or wound healing: Biomarkers and non-invasive technologies such as imaging for patient stratification and clinical markers • Enhanced drug delivery (parenteral delivery devices/technologies, novel formulations, target organ delivery, sustained or controlled release technologies) • New mechanistic pathways or targets regulating responses to tissue injury and repair processes • Novel approaches to diseases whose pathology is associated with acute or chronic tissue injury, such as idiopathic pulmonary fibrosis, acute/chronic kidney diseases, liver fibrosis/cirrhosis, adhesions, excessive scarring • Healthcare solutions for tissue repair, especially advanced wound care

Partnering Contacts External Opportunity contact: Chang S. Hahn Ph.D. Director, Portfolio Strategies and External Opportunities Fibrosis and Wound Repair TSU BRW G-303A, Route 202-206 Bridgewater NJ 08807 USA Tel: +1 908 231 4000 [email protected] Business Development contact: John Orsato Associate Vice-President, Novel Therapeutic Approaches & Infectious Diseases 174 avenue de France 75635 Paris cedex 13 – France Tel: +33 1 53 77 40 00 [email protected]

Existing alliances/ partnership: • Regeneron • Various academic collaborations

Infectious Diseases The strategy of the group in Infectious Diseases aims to discover and develop innovative healthcare solutions or compounds with superior benefits for prevention, diagnosis and treatment of infectious diseases with high medical need. Our key focus of internal and external innovation is on global solutions for multi drug-resistant infections in hospitals and nursing homes, together with sanofi pasteur, the Vaccines Division of the group, and solutions for neglected diseases in developing countries, in alignment with our Access to Medicines strategy.

Domains of interest Multi-drug infections in hospital and nursing home settings (Hospital – or community acquired – resistant infections) • Anti-bacterials, anti-fungals and bacterial toxins inhibitors • Prophylactic approaches (e.g. virulence factors, biofilms) and other therapeutic needs • Diagnostics, disinfectants Neglected diseases in developing countries: • Tuberculosis: treatment for non-resistant and resistant tuberculosis. Treatment of latent tuberculosis infections • Parasitic diseases: Malaria (uncomplicated/severe), Leishmaniasis (visceral and cutaneous)/Sleeping sickness (Human African trypanosomiasis, stage I/II), Chagas disease • Other therapeutic needs Host oriented compounds/healthcare solutions: • Activity on human targets/pathways involved in host response to pathogens (viruses, bacteria, parasites) including prevention, treatment and other secondary effects of infections Preventive and therapeutic approaches are based on: • Innovative targets, modes of action, technologies for identifying new treatments • Small Molecules or Natural Products • Biologics (antibodies, proteins...) • Others

Existing alliances/ partnership: • • • • • • • • • •

Alopexx AVIESAN DNDI INNOMAD John Hopkins University MMV Novozymes Palumed Regeneron University of Chicago

Partnering Contacts External Opportunity contact: PETER HAMMANN, PROF. DR. Head External Opportunities Industriepark Hoechst, Bldg H 831 D-65296 Frankfurt Germany Tel: +49 69 395 80710 [email protected] Business Development contact: John Orsato Associate Vice-President, Novel Therapeutic Approaches & Infectious Diseases 174 avenue de France 75635 Paris cedex 13 – France Tel: +33 1 53 77 40 00 [email protected]

14/15

Immuno-Inflammation The mission of the Immuno-Inflammation Unit of sanofi-aventis R&D is to provide innovative healthcare solutions in the interest and to the benefit of patients. Our current focus is on major immunological and chronic inflammatory disorders of both genetic and epigenetic origin that represent true unmet medical needs today and in the future. Multiple factors or processes such as the living environment, nutrition behavior or aging status are known to markedly influence both severity and chronicity of clinical manifestations.

Domains of interest • First in class and/or best in class, disease-modifying therapeutics (small molecules, biologics, natural products, botanicals, RNA, DNA , protein epitope mimetics, next generation antisense) aimed toward common immuno-inflammatory diseases such as chronic obstructive pulmonary disease (COPD), psoriasis, inflammatory bowel disease (IBD), multiple sclerosis (MS), rheumatoid athritis (RA) and asthma • Leapfrogging, “game-changing” therapeutics addressing underserved immuno-inflammatory diseases such as systemic lupus erythematosus (SLE or Lupus), age-related macular degeneration (AMD), IgA nephropathy, dermatomyositis, uveitis • Technologies enabling targeted drug delivery to organ(s) of interest that will lead to safer and more effective therapies for patients with immuno-inflammatory diseases • Formulation enhancements facilitating patient-focused solutions to unmet patient and provider needs, such as more convenient or otherwise improved dosing regimens (nanoparticles, microbiomebased delivery, improved devices, novel chemistry approaches to drug metabolism) • Proteome and genome-based patient care solutions including phenotypic profiling, immunologic or genetic signatures, sophisticated diagnostics or innovative bioassays • Novel scientific insights into key signaling pathways common to immuno-inflammatory conditions that will lead to improved approaches to selective immunosuppression, mucosal repair, disease susceptibility or modulation of immune system cross-talk • Opportunities at any stage of development from discovery to proof of efficacy

Existing alliances/ partnership: • • • • • • • •

Abbott Hopital Civil de Lyon John Hopkins University Kyowa Hakko Kirin Co., Ltd Mount Sinai Medical Center NIH Regeneron University of California

Partnering Contacts External Opportunity contact: Patrick Griffin Head, External Innovation and Opportunities Immuno-Inflammation Therapeutic Strategy Unit 200 Crossing Boulevard Bridgewater, New Jersey 08807-0890 Tel: +1 908 231 4000 [email protected] Business Development contact: Aude Le-Roux PhD Associate VP Immuno-inflammation 174 avenue de France 75635 Paris cedex 13 – France Tel: +33 1 53 77 40 00 [email protected]

Biologics Sanofi-aventis has the ambition to become a major player in the field of Biotechnology. With this in mind, the group is proactively developing external partnerships to increase the biologics portion in the sanofi-aventis R&D portfolio through both internal and external innovation. This strategy has already provided fruitful results to the group with its share of biotechnology-sourced products in its pharma portfolio (excluding vaccines) increasing from 14% in 2009 to 31% in April 2010. Sanofi-aventis activities in biotechnology integrate the value chain from molecule design to all development activities required for submission of biologic products. The group has two fully integrated biotechnology platforms located in France (Vitry-sur-Seine, near Paris) and Germany (Frankfurt-Hoechst site), plus a research unit in the US. A major investment has been made in the Vitry-sur-Seine site to help to create one of the largest cell culture biotechnology units ever built in France. In addition, two specific innovation platforms of expertise are dedicated to nucleic acid therapeutics and stem cells.

Domains of interest Novel Therapeutics: • Clinical-stage antibodies or other biological products with the potential to address key unmet medical needs in the sanofi‑aventis Therapeutic Strategy focus areas • RNA therapeutics in late discovery or early clinical stages • Stem cell and/or regenerative medicine products in early clinical stages

Existing alliances/ partnership: Products: • Alopexx • Dyax • Kyowa Kirin • Merrimack Pharmaceuticals • Micromet • Novozymes • Regeneron • Rockefeller University Technologies & Manufacturing: • BioWa • Celltrion • Dyax • Lonza • Regeneron Basic Research: • AVIESAN • California Institute of Technology • Harvard Stem Cell Institute • Salk Institute • Shanghai Institute for Biomedical Science • University of Pennsylvania

New scaffolds: • New protein scaffolds for next generation mono or multispecific biotherapeutics New platforms and technologies: • New cost effective manufacturing processes, including miniaturized high-throughput platforms for media/culture improvement • Low cost efficient purification platforms for biotherapeutic products. • New assay methodologies • New ways to rapidly select functional biological entities for protein, nucleic acid or cell based applications Manufacturing: • Cost effective manufacturing facilities for rapid/flexible generation of biological products

Partnering Contact External Opportunity contact: MELVYN HOLLIS VP Bionetwork & Program Management 270 Albany Street, Cambridge, MA 02139, USA Tel: +1 617 679 5600 [email protected]

16/17

Exploratory Unit

Asia Pacific

Exploratory Unit (EU) is the primary source of early and open innovation of sanofi-aventis. The mission of EU is to advance basic scientific knowledge, to understand the underlying causes of diseases and to translate emerging ideas into validated concepts foreshadowing industrial applications for patients’ benefits.

We address the specificities of the Asia-Pacific region by developing adapted healthcare solutions for diseases related to this region. These include specific cancers (such as hepatocellular carcinoma, gastric, oesophageal and nasopharyngeal); but also certain infectious diseases, including Hepatitis B virus; among others.

EU activities are driven by scientific excellence and innovation and bridge academic multi-disciplinary research with sanofi-aventis scientists. EU, in partnership with academic and advanced research institutions, also assesses and incubates emerging ideas which are too under-developed to get attention from other entities of sanofi‑aventis R&D. Extending its scientific networks, EU also fosters exchange especially by integration of renowned visiting scientists within EU teams.

We are also exploring emergent opportunities in Asia-Pacific including traditional Chinese medicine, nutraceuticals, biosimilars, stem cell research and personalized medicine.

Partnering Contact Jean-Jacques Robert, Ph.D, MBA Head of Partnering & Scientific Networks Exploratory Unit, Centre de Labège Voie La Pyrénéenne, BP37202 31672 Labège cedex – FRANCE Tel: +33 5 61 00 43 04 [email protected]

“The partnership with sanofi-aventis has greatly enhanced our ability of translational research. Moreover, it diversified the collaborative models for domestic institutes like SIBS to work with global pharmaceutical companies like sanofi-aventis.” Dr. Jiarui Wu Vice President of SIBS

Partnering Contact Geneviève Bellocq Unit Management office Head Sanofi-aventis R&D 1 avenue Pierre Brossolette 91385 Chilly Mazarin – France Tel: +33 1 60 49 77 77 [email protected]

Early to Candidate The mission of the Early to Candidate (E2C) Unit is to take on validated concepts and early stage leads, coming from sanofi-aventis or from academic or biotech partners, and transform them into pharmacological tools or (pre-)candidates with established therapeutic orientations for clinical proof of concept, either within sanofi-aventis or with external partners. The Early to Candidate Unit is interested in validated concepts and targets coming from all domains that will give rise to innovative products within the six major areas of the group (Diabetes, Oncology, Aging, Immuno-Inflammation, Infectious Diseases, Fibrosis and Wound Repair) and any other opportunistic areas of interest.

Partnering Contacts Worldwide, France and rest of the world Carole Fages, Ph.D, MBA Head of E2C Unit Development Office 371, rue du Professeur Blayac 34184 Montpellier cedex 04 – France Tel: + 33 4 99 77 78 79 [email protected] US Paul R. Eynott, PhD US Head, Partnering & Innovation Early to Candidate Distinct Project Unit (DPU) Sanofi-aventis, US 2090 East Innovation Park Drive Oro Valley, Tucson, Arizona, 85755 Tel: +1 520 544 5801 [email protected] Asia-Pacific Alex Zhang, PhD Asia-Pacific Head of E2C Unit Sanofi-aventis R&D China 5/F, No.112 Jianguo Road, Chaoyang District Beijing 100022, P.R.China Tel: +86 10 6563 4936 [email protected]

Lead Generation to Candidate Realization The Lead Generation to Candidate Realization (LGCR) platform identifies small molecule leads and progresses them up to registration. The activities range from target assessment and hit finding to dossier filing, including lead generation and optimization, drug design, natural products and CMC. The Lead Generation to Candidate Realization platform in return offers a unique integration of scientific expertise and competencies from target to registration filings, in various fields such as hit finding, structural biology, drug design, lead generation and optimization and CMC development activities. By sharing some of our key assets, capabilities and technology platforms, LGCR will be your partner for adding value to your ideas and compounds through a variety of collaborative and risk-shared business models. We are open and willing to turn R&D passion into fruitful partnerships.

Domains of interest • • • • • • •

Solutions for poorly drugable & intractable targets Cellular disease models for phenotypic screening Compound collections and focused libraries Protein chemistry Fragment based screening Systems biology informatics High potent chemistry and new synthetic chemistry technologies • Drug Delivery Systems and Process Technologies

Partnering Contact Denis Croisat, Ph.D LGCR Sourcing & External Business opportunities Sanofi-aventis 1, avenue Pierre Brossolette 91385 Chilly Mazarin cedex – FRANCE Tel: +33 1 60 49 77 77 [email protected]

18/19

Pharmaceutical Customer Solutions Pharmaceutical Customer Solutions (PCS) is sanofi-aventis global center of excellence in prescription medicine beyond oncology and diabetes to address the needs of our various customers: patients and their families, healthcare professionals and payors. PCS combines the expertise from Medical and Marketing teams but also Market Access, Customer Insight Assessment, Forecasting, Patrimony Management and Product Communications, with the commitment to: • define and orchestrate global product strategies, for major brands; • transform promising compounds and projects under development into innovative therapeutic solutions improving patient healthcare and quality of life. PCS partners with R&D, Business Development and Industrial Affairs to accelerate the identification of attractive opportunities for unaddressed patient needs in a systematic and proactive way. Our scope of activity covers the following: Products : Prescription products, except Diabetes, Oncology, Vaccines and Generics Disease Areas: Priority given to diseases where sanofi-aventis has an established portfolio and know-how, but also to any attractive unmet medical need especially if consistent with our R&D’s strategic priorities Healthcare Services: Our ambition is not only to market products per se but also to develop devices and services fueling our brand equity

Existing alliances/ partnership: We have a long history of partnerships for the licensing, co-promotion or co-marketing of products, such as our alliances with: • Bristol-Myers-Squibb • Daiichi-Sankyo • Procter & Gamble These partnerships have ensured the worldwide success of: Plavix®, Aprovel®, Actonel® and Tavanic®

Domains of interest • Co-development, licensing, co-marketing, co-promotion of innovative prescription products • Innovative device approaches • Healthcare services bringing solutions to our customers (patients, healthcare professionals, payors): – improved continuum of care and disease management, – better access to health information, – patient quality of life and peace of mind, – improved treatment adherence.

Partnering Contacts Partnerships on anti-arrhythmic drugs and cardiac rhythm management devices: Aurélie-Anne CHAUSSE Senior Manager, New Business Opportunities Tel: +33 1 55 71 40 00 [email protected]

Partnerships on Plavix®, Aprovel®/Avapro® or associated fixed-dose combinations: Dominique ROOME Associate Vice-President, Strategic Mature Products Tel: +33 1 55 71 40 00 [email protected]

Partnerships on heparins: Alexandre MOREAU Vice-President, Global Strategy – Heparins Tel: +33 1 55 71 40 00 [email protected]

Projects linked to prescription drugs in all other therapeutic areas: Ophra REBIERE Vice-President, Strategic Portfolio Expansion Tel: +33 1 55 71 40 00 [email protected]

For any other healthcare solutions (including devices and services): Emma GARDE Senior Project Manager, Healthcare Solutions & Partnerships Tel: +33 1 55 71 40 00 [email protected] Mail address: 174 avenue de France BP374 75635 Paris cedex – FRANCE

Prospective and Strategic Initiatives Dedicated teams close to you, all over the world

Prospective and Strategic Initiatives (PSI) is an R&D department committed to anchoring sanofi-aventis in innovation hotspots and bringing distinctive external opportunities to all units and platforms. In addition to its global scouting organization, with dedicated teams in some of the top innovation hotspots around the world, PSI contributes to the assessment of external opportunities, leads major alliances and consortia, drives strategic initiatives in R&D and incubates some of the new platforms. Prospective and Strategic Initiatives’ scouting and partnering teams are fully dedicated to: • Being globally connected • Being locally active and embedded in local innovation ecosystems • Identifying and working with local innovators and bringing their ideas, concepts and energy to the best, most appropriate contacts within the sanofi-aventis group Being as close and accessible to you is our aim, knowing you better and interacting efficiently with you is our will and partnering with you is our determination.

Jacques DELORT Vice President Prospective Strategic Initiatives

Partnering Contacts US

Germany Shiv Krishnan, PhD Senior Director, Scouting & Partnering Sanofi-aventis R&D, 1041 Route 202-206 Bridgewater, New Jersey 08807, USA Tel: +1 908 541 5333 [email protected]

US – West Coast

Harald Pacl, PhD Senior Director Scouting & Partnering Germany Sanofi-Aventis Deutschland GmbH D-65926 Frankfurt am Main, Germany Tel: +49 69 305 80644 [email protected] France and rest of the World

Rémi Brouard, MD. Vice President Scouting & Partnering Sanofi-aventis office in San Diego: Scripps Translational Science Institute building 3344 North Torrey Pines Court, suite 300 La Jolla, California, 92037 USA Tel: +1 858 558 85 28 s&p-westus.psi @sanofi-aventis.com

Isabelle Thizon-de-Gaulle, MD Vice President Scouting & Partnering France & rest of the world 174 avenue de France 75635 Paris cedex 13 – France Tel: +33 0 1 53 77 40 00 [email protected]

US – North East Sridaran Natesan, Ph.D. Senior Director, Scouting & Partnering Prospective & Strategic Initiatives Sanofi-aventis 270, Albany Street, Cambridge, MA 02139 Tel: +1 617 679 5717 s&p-eastus.psi @sanofi-aventis.com

20/21

Worldwide Connected Network of Selected Partners

EUROPE Biotech • Genfit, Lille, France • Novozymes, Bagsvaerd, Denmark • Oxford BioMedica, Oxford, UK • Zealand Pharma, Glostup, Denmark

USA Biotech • AgaMatrix, Salem, NH, USA • Alopexx, Cambridge, MA, USA • CureDM, Wilmington, DE, USA • Dyax, Cambridge, MA, USA • Exelixis, San Francisco, CA, USA • ImmunoGen, Cambridge, MA, USA • Merrimack, Cambridge, MA, USA • Micromet, Bethesda, MD, USA • Regeneron, Tarrytown, NY, USA • Syntiron, St Paul, MN, USA • Wellstat, Gaithersburg, MA, USA Academia • California Institute of Technology, Pasadena, CA, USA • Johns Hopkins University, Baltimore, MD, USA • Rockefeller University, New-York, NY, USA • Salk Institute for Biological Studies, La Jolla, CA, USA • University of Pennsylvania, Philadelphia, PA, USA Acquisition • BiPar Sciences, CA, USA

Academia/CONSORTIA • AVIESAN (French Life Sciences and Healthcare Alliance) • Innovative Medicines Initiative (IMI) – European Public Private Partnerships • Institut de la Vision, Paris, France Acquisition • Fovea, Paris, France

ASIA Biotech • BioWa, Japan • Huya, China • Kitasato Institute research center for biologicals, Japan • Kyowa Kirin, Japan Academia • Institute of Hematology and Blood Diseases, Tianjin, China • Khotro/Khidi, Korea • SIBS, China Acquisition • Shantha Biotechnics, Hyderabad, India

Recent Deal Flow Overview REGENERON ROCKEFELLER UNIVERSITY

MICROMET WELLSTAT THERAPEUTICS

CALIFORNIA INSTITUTE OF TECHNOLOGY

FOVEA OXFORDBIOMEDICA

EXELIXIS

BIPAR

ALOPEXX

MERRIMACK

SYNTIRON

KYOWA HAKKO KIRIN

CUREDM

KALOBIOS

BIOWA

AVIESAN SHANTHA BIOTECHNICS

AGAMATRIX

SALK INSTITUTE

JAN

FEB Q1 – 09

MAR

APR

MAY Q2 – 09

JUN

JUL

AUG Q3 – 09

SEP

OCT

NOV Q4 – 09

DEC

JAN

FEB

MAR

APR

Q1 – 10

22/23

Industrial Affairs

Sales & Marketing

A global approach to manufacturing

Sanofi-aventis has a broad portfolio of prescription medicines, vaccines, consumer healthcare (OTC) products and generics with a market presence across both traditional and emerging markets.

The group currently has a comprehensive manufacturing network, with global sites for the creation of medical equipment, systems and technologically advanced products; regional sites dedicated to high volume mass market product brands; and local factories focused on providing for national market needs. In order to manage the growth of its manufacturing tool, in 2009 the group adopted a policy of Unique Quality and created an international and transversal quality organization structure, uniting the R&D, Manufacturing, sanofi pasteur and Pharmaceutical Operations teams. Furthermore, a management team for Manufacturing Development and Innovation was created in June 2009. Its purpose is to lead and manage the lifecycle of the whole portfolio of products (Innovative Medicines, Consumer Healthcare, Generics and Medical Equipment) by developing products and administration systems that respond to the unmet medical needs of patients all over the world.

83.3 8

distribution platforms

3.3

billion units produced in 2009

Broad set of Businesses contribute to growth: SECTORS

2009 NET SALES

SANOFI PASTEUR

3,483

+19.2%

SANOFI PASTEUR MSD

1,132(1)

-11.0%

CONSUMER HEALTHCARE

1,430

+26.8%

GENERICS

1,012

+198.0%

ANIMAL HEALTH

2,554

+0.4%

(in millions of euros)

CHANGE ON A COMPARABLE BASIS

(1) Not consolidated

US

EU Sales2009

(millions euros)

REST OF WORLD Sales2009

(millions euros)

Sales2009

(millions euros)

€ 9,426 € 12,059 € 7,821

For more information, please visit:  

 ww.sanofi-aventis.com w www.sanofipasteur.com

FORWARD LOOKING STATEMENTS This document contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include product development, product potential projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future events, operations, products and services, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates,” “plans” and similar expressions. Although sanofi-aventis’ management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of sanofi-aventis, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMEA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such products candidates, the absence of guarantee that the products candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives as well as those discussed or identified in the public filings with the SEC and the AMF made by sanofi-aventis, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in sanofi-aventis’ annual report on Form 20-F for the year ended December 31, 2009. Other than as required by applicable law, sanofi-aventis does not undertake any obligation to update or revise any forward-looking information or statements.

Photo credits: sanofi-aventis – Hubert Mouillade and Beatrice Devenes.

“By working together, let us share our passion for innovation to make a difference in patients’ lives”

Updated June 2010   US.COR.10.06.001

Partner to your idea

Scientific Communications Sanofi-aventis R&D 1, avenue Pierre Brossolette 91385 Chilly Mazarin cedex, FRANCE Tel: +33 1 60 49 77 77

www.sanofi-aventis.com